I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
What would genuinely help is knowing whether the fasting requirement is as strict in practice as the label implies, and what people actually see when they get it wrong.
Not looking for reassurance. Looking for the part I have got wrong.
Answering the narrow version, because the broad one does not have a single answer. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
TrialNerd_Beth said:Orforglipron is the more interesting oral story because it is not a peptide at all.
No disagreement with TrialNerd_Beth. One condition attached. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsEndoResFellow said:I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
Can confirm the pattern EndoResFellow describes. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.